About Intelligent Retinal Imaging Systems
Intelligent Retinal Imaging Systems (IRIS) develops a retinal telemedicine assessment service based on technology developed at the Florida Institute for Human and Machine Cognition. IRIS's technology is targeted at preventing two of the leading causes of blindness in adults: diabetic retinopathy and glaucoma. IRIS's systems were developed by retina specialty physicians to more efficiently diagnose the early stages of preventable eye disease, giving patients and physicians unprecedented access to drive quality outcomes and reduce the cost of care.
Expert Collections containing Intelligent Retinal Imaging Systems
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Intelligent Retinal Imaging Systems is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Latest Intelligent Retinal Imaging Systems News
Oct 11, 2019
Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more service providers to successfully adopt a telemedicine program into their practices to examine, detect and diagnose retinal disease in diabetic patients, according to a company news release. “The IRIS and Remidio partnership will have a powerful impact on healthcare providers seeking to close care gaps and create better outcomes for their patients with diabetes,” Steve Martin, CEO of IRIS, said in a company news release. “The Remidio device is portable, affordable and takes high quality images, which supported by the IRIS algorithms will make it much easier to provide sight-saving exams to patients with diabetes.” The Remidio portable, smartphone based fundus cameras have been validated against high-end desktop imaging systems, in peer reviewed publications in PLOSOne, Nature Eye, Ophthalmology Retina, JAMA Ophthalmology, to name a few. The use of artificial intelligence (AI) is enhancing the way retinal screenings can prevent blindness. The Remidio camera provides cutting edge, AI-ready capabilities, such as providing instantaneous image gradeability on the camera, so that the end user knows if the image is able to be graded for diagnosis. This is a critical feature, as the industry is moving to providing retinal exams in settings where there is limited connectivity, such as people’s home, on buses where screenings are performed, at screening events, as well as office settings. Partnering the capabilities of the IRIS and Remidio teams together will allow for collaboration on ways their combined technologies can improve diagnosing disease and preventing blindness. IRIS was created for early identification of diabetes in patients to improve outcomes and to reduce downstream healthcare costs. This comprehensive solution, which just surpassed the milestone of performing over 500,000 patient exams, includes simple to use cameras, a secure, HIPAA compliant software platform, and a seamless electronic medical record (EMR) integration providing accurate diagnoses back to the ordering physician. Unlike others in the retinal telemedicine space, IRIS is the only solution that offers the highest gradeability rate in the industry, due in part to the caliber of the cameras, like Remidio, but also as a result of in-depth camera training and proprietary algorithms that IRIS has developed to enhance the images and allow for an effective diagnosis to be performed. Remidio is an ISO13485-certified integrated medical device and artificial intelligence company seeking to enhance healthcare access by creating technologies that are smart and easy to use. “By partnering with IRIS, we are part of a complete program that aligns and supports the IRIS mission to challenge the status quo, empower providers to face changing practice patterns, and deliver early detection of diabetic eye disease in primary care,” Dr. Anand Sivaraman, CEO of Remidio Innovative Solutions, said in the news release. “This partnership is coming at the right time, with the per patient annual cost of managing diabetes at over $13,000 in the United states. We seek to bring this cost down by 30% through early detection, management, and treatment, with IRIS using Remidio non-mydriatic fundus on phone cameras.” Recent Content
Intelligent Retinal Imaging Systems Frequently Asked Questions (FAQ)
When was Intelligent Retinal Imaging Systems founded?
Intelligent Retinal Imaging Systems was founded in 2012.
Where is Intelligent Retinal Imaging Systems's headquarters?
Intelligent Retinal Imaging Systems's headquarters is located at 2 N Palafox Street, Pensacola.
What is Intelligent Retinal Imaging Systems's latest funding round?
Intelligent Retinal Imaging Systems's latest funding round is Loan.
How much did Intelligent Retinal Imaging Systems raise?
Intelligent Retinal Imaging Systems raised a total of $14M.
Who are the investors of Intelligent Retinal Imaging Systems?
Investors of Intelligent Retinal Imaging Systems include Paycheck Protection Program, Providence Ventures, Ballast Point Ventures, CoxHealth, Florida Institute for the Commercialization for Public Research and 3 more.
Who are Intelligent Retinal Imaging Systems's competitors?
Competitors of Intelligent Retinal Imaging Systems include Digital Diagnostics and 2 more.
Compare Intelligent Retinal Imaging Systems to Competitors
RetinAI supports eye care professionals and patients throughout the medical examination process using artificial intelligence (AI). Its solutions rely on advances in medical image analysis, ophthalmology, and machine learning. The company was founded in 2017 and is based in Bern, Switzerland.
Viderai provides retinal analysis using artificial intelligence to patients. It offers products that help specialists diagnose patients with diseases such as diabetic retinopathy and its primary clients are ophthalmologists and public healthcare insurance companies. The company was founded in 2019 and is based in Ostrava, Czech Republic.
Retina Labs provides telehealth and virtual care solutions for eye care professionals. The cloud-based iVision teleophthalmology and live teleconsult platform streamlines the management of chronic eye diseases such as diabetic retinopathy, glaucoma, age related macular degeneration and retinopathy of prematurity. iVision provides eye care professionals a comprehensive solution that combines advanced ocular imaging, clinical interpretation and reporting tools with integrated Electronic Medical Records, Practice Management and electronic referrals.
Zilia is the developer of Zilia Ocular, a fondus camera enabling non-invasive, continuous, quantitative, and accurate measurements of oxygenation in targeted regions of the eye fundus, such as the optic nerve head, the retina, or the macula.
Retina Technologies is a medical device company that develops the OcuVue digital vision screening platform to help eliminate treatable vision loss and blindness by enabling early detection and prevention. It aims to end needless vision loss and blindness for everyone across the globe. It was founded in 2018 and is based in New York, New York.
Phelcom Technologies is a developer of medical devices, including Phelcom Eyer, a portable retinal camera.